In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats. Trump ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug giant announced Tuesday. Merck has opened a $1 billion, 225,000-square ...

Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic improvement at Week 12 of its phase 2 ulcerative colitis trial. The new duvakitug data also clear up the ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...